71 件 ・ 関連度順
概要と使いどころ
Routes between five assessment pathways — formative, rubric/criteria, authentic/performance, peer/self, and diagnostic — with validity and equity checks. Use when a teacher needs help choosing how to assess.
日本語の概要は準備中です。原文の説明を表示しています。
Use when interpreting biological research findings, evaluating life science evidence, analyzing molecular or cellular mechanisms, comparing competing biological hypotheses, designing or critiquing experiments in biology, genetics, genomics, cell biology, immunology, neuroscience, ecology, or any life science domain. Triggers on questions about gene function, pathways, phenotypes, GWAS hits, single-cell data, animal models, clinical translation, evolutionary arguments, or any biology/life science reasoning task.
日本語の概要は準備中です。原文の説明を表示しています。
Biochemical metabolism of macronutrients and key micronutrients — digestion, absorption, transport, utilization, and excretion — with emphasis on the pathways that matter for dietary-guideline debates (insulin response, lipoprotein metabolism, one-carbon metabolism, iron homeostasis). Use when a question asks what happens biochemically to a food after it is eaten, or when a claim about "metabolic effect" needs to be tested against mechanism.
日本語の概要は準備中です。原文の説明を表示しています。
Assessing anthropogenic environmental impacts — pollution pathways, habitat destruction and fragmentation, land-use change, invasive species, overharvest, and extinction debt. Covers environmental impact assessment (EIA) methodology, exposure-effect relationships, population viability analysis, IPAT and ecological footprint frameworks, and strategic environmental assessment. Use when quantifying or forecasting human impacts on ecosystems, designing monitoring programs, or evaluating a proposed intervention against a baseline.
日本語の概要は準備中です。原文の説明を表示しています。
Brain-Computer Interface with colored operad security boundaries. Maximally isolated EEG/neural data processing via VM→Container→Process enclosure with GF(3) conservation for Agent-O-Rama neural pathways.
日本語の概要は準備中です。原文の説明を表示しています。
Comprehensive audit of a user's entire Claude environment — combines Project audit (six-dimension Project Scorecard, seven anti-patterns) with Global audit (six-dimension Global Layer Scorecard) plus Cross-Layer Alignment Check across all nine layers and Evolutionary Recommendations across four pathways. Produces a unified action plan. Use when user says "full audit of everything," "audit my entire Claude setup," "full stack audit," "comprehensive review of my project and preferences," "check everything," or wants the complete health check of both a specific Project AND their global configuration. Also use when a project audit reveals cross-layer issues that require full-stack visibility. Do NOT use for auditing only a Project (use rootnode-project-audit if available) or only global layers (use rootnode-global-audit if available). Do NOT use for single prompt evaluation (use rootnode-prompt-validation if available). Run on Opus 5 or Sonnet 5 at `high` effort (both defaults); depth reduces on legacy models.
日本語の概要は準備中です。原文の説明を表示しています。
Systematically interpret mass spectra to determine molecular formula, identify fragmentation pathways, and propose molecular structures. Covers ionization method assessment, molecular ion identification, isotope pattern analysis, common fragmentation losses, and purity evaluation.
日本語の概要は準備中です。原文の説明を表示しています。
Query the Precision Medicine Knowledge Graph (PrimeKG) for multiscale biological relationships across genes and proteins, drugs, diseases, phenotypes, pathways, biological processes, exposures and anatomy. Use this skill to search entities by name, pull direct neighbours and their evidence types, summarise the local network around a disease, and find direct or two-hop drug-disease connections for repurposing hypotheses. Also trigger on PrimeKG, kg.csv, Harvard Dataverse knowledge graph, disease_protein, drug_protein, indication and contraindication edges, or network pharmacology over a biomedical knowledge graph.
日本語の概要は準備中です。原文の説明を表示しています。
Use this agent when you need to create a pathway summary for a gene after completing the main gene review. This agent should be invoked specifically to generate GENE-pathway.md files that summarize the gene's role in biological pathways with proper citations and mermaid diagrams.
日本語の概要は準備中です。原文の説明を表示しています。
Use when a task needs the judgment of a Biofuels/Biodiesel Technology and Product Development Manager — deciding whether a lab/bench-scale process is ready to scale up, evaluating feedstock flexibility tradeoffs in process design, pricing a technology's value against regulatory credit pathways (RFS RIN, LCFS CI score), or managing IP strategy for a novel conversion process. Distinct from biofuels-production-manager, which runs an existing operating facility — this role owns R&D and commercialization of new or improved process technology.
日本語の概要は準備中です。原文の説明を表示しています。
Drafts FDA 510(k) Premarket Notification submissions demonstrating substantial equivalence under 21 CFR Part 807. Supports Traditional, Special, and Abbreviated pathways. Use when preparing Class II medical device regulatory filings, substantial equivalence analyses, or FDA premarket submissions.
日本語の概要は準備中です。原文の説明を表示しています。
Expert-level medical device design covering regulatory pathways, design controls, biocompatibility, sterilization, risk management, and verification and validation.
日本語の概要は準備中です。原文の説明を表示しています。
Knowledge base from the DoD Risk, Issue, and Opportunity (RIO) Management Guide for Defense Acquisition Programs (OUSD R&E, Sep 2023 incl. Change 2.2). Use for the defense-acquisition mechanics of program risk management: the RIO definitions (risk/issue/opportunity), the five-step risk process (plan-identify-analyze-mitigate-monitor), 1-5 likelihood/consequence scoring and the 5x5 risk matrix, the four mitigation options (accept/avoid/transfer/control), burn-down plans, issue management (probability=1), opportunity management toward should-cost, cross-program/interface risk, tailoring RIO to the six AAF acquisition pathways (UCA/MTA/MCA/Software/DBS/Services), specialized methods (RMF, MBCRA/Cyber Table Top, Agile metrics, FMECA, ITRA/DTRAM), and institutionalizing RIO via the PRMP, boards (RMB/JRMB/ROMB/RWG), tools, tiered roles, and WBS/IMP/IMS/EVM/TPM integration. This is the DoD-acquisition complement to nasa-risk (general CRM/RIDM theory) and dau-se-guidebook (the SE process frame). Does NOT teach general risk theory from scratch, and defers specialized risk regimes (system safety/ESOH, HSI, detailed cyber/RMF, spectrum) to their own DoD instructions and the relevant packs.
日本語の概要は準備中です。原文の説明を表示しています。
Knowledge base from the OUSD(R&E) guidebook Implementing a MOSA in DoD Programs (Feb 2025). Use for the Modular Open Systems Approach as a DoD acquisition + design discipline: the statutory/regulatory basis (10 U.S.C. 4401–4403, FY2017/FY2021 NDAA, DFARS), the five OUSD(R&E) pillars, the plan→modularize→identify→define→standardize interface lifecycle, technical levers (WBS/MIL-STD-881F taxonomy, standards profiling, API-first software, COTS/cybersecurity), MOSA assessment metrics and tools (PART/OAAT/KOSS/SEAM/MAUT), technology-change and DMSMS management, roadmaps, MOSA across the six AAF pathways, and contracting/IP/data-rights mechanics. SCOPE LIMITS: this is U.S. DoD weapon-system acquisition policy, not a general open-architecture or interface-standards reference — it names standards (FACE, OMS, DISR) without reproducing them, is light on detailed engineering of any specific standard, and does not cover the underlying SE processes (use dau-se-guidebook / nasa-npr-7123) or general systems-engineering theory (use sebok).
日本語の概要は準備中です。原文の説明を表示しています。
Knowledge base from the DoD Test & Evaluation Enterprise Guidebook (OUSD R&E, August 2022). Use for DoD test and evaluation (T&E) across the Adaptive Acquisition Framework — the four test communities (contractor testing, developmental DT&E, operational OT&E, live-fire LFT&E); the five operational events (Operational Demonstration, EOA, OA, IOT&E, FOT&E) and the OTRR gate; the T&E Strategy / TEMP and its IDSK, with the upstream documents that feed it and the test plans that decompose it; the T&E organizations and oversight roles (USD(R&E), DOT&E, TRMC, the Service Executives and OTAs, the T&E WIPT, CDT); and pathway-specific T&E for all six acquisition pathways (Urgent Capability, Middle Tier, Major Capability, Software, Defense Business Systems). Statutory anchors include 10 U.S.C. §4171 (IOT&E) and §4172 (LFT&E/FUSL). This is guidance, not policy: it points outward to DoDI 5000.89 and the DoDI 5000-series for binding detail, and is thin on detailed test statistics/design-of-experiments methodology, cost estimating, the Acquisition of Services pathway, and any CUI/CAC-gated companion guides.
日本語の概要は準備中です。原文の説明を表示しています。
Orchestrates the untargeted LC-MS metabolomics pipeline end-to-end (xcms 4.x feature extraction, QC/drift/normalization, confidence-stratified annotation, permutation-validated statistics, background-aware pathway mapping), naming what each stage decides and where it silently fails. Use when running a full LC-MS metabolomics study from raw mzML to enriched pathways and needing the honest handoffs between stages. Each stage defers to its component skill for parameters and traps; for stable-isotope flux (a separate branch, not this untargeted flow) see metabolomics/isotope-tracing.
日本語の概要は準備中です。原文の説明を表示しています。
Lipid analysis and lipid-disease associations using LIPID MAPS classification, HMDB metabolite data, KEGG/Reactome lipid pathways (sphingolipid, eicosanoid, steroid, fatty acid), and PubChem chemical info. Use for lipid identification, lipid metabolism pathway mapping, and lipid-associated disease analysis (cardiovascular, diabetes, NAFLD).
日本語の概要は準備中です。原文の説明を表示しています。
Drug regulatory and approval research — FDA substance registry, ATC/EPC classification, EMA decisions, generic-drug status, FDA Orange Book exclusivity, NDA/BLA pathways. Use for jurisdiction-aware approval status (FDA vs EMA), generic vs brand availability, exclusivity expiry tracking, and regulatory pathway selection. Always specifies the market when reporting status.
日本語の概要は準備中です。原文の説明を表示しています。
Drug and chemical toxicity assessment via adverse outcome pathways (AOPs), real-world FAERS adverse event signals, FDA labels, and toxicogenomic associations. Triangulates molecular initiating event to cellular outcome to organ-level toxicity to clinical adverse event. Use for hepatotoxicity/cardiotoxicity/nephrotoxicity prediction and toxicology reports.
日本語の概要は準備中です。原文の説明を表示しています。
Interpretable ADMET analysis with mechanistic reasoning. Maps liabilities to structural causes and biological pathways. Based on CoTox (Park 2025) and DrugR (Liu 2026).
日本語の概要は準備中です。原文の説明を表示しています。
Biological knowledge: query curated assertions and reference databases for genes, variants, pathways, regulation, cell types, reference atlases, perturbation-derived relationships, phenotypes, therapeutic targets, drugs, interactions, annotations, signatures, compounds, and predicted structures. Use for identifiers, marker sets, gene sets, associations, ontologies, database facts, and cross-database coverage.
日本語の概要は準備中です。原文の説明を表示しています。
Build EcoSIM atmospheric greenhouse-gas forcing files by combining a historical monthly atmgas NetCDF with RCMIP/CMIP6 SSP concentration pathways. Use when Codex needs SSP245/SSP585 or other SSP atmospheric CO2, CH4, and N2O concentrations, key-year tables, or scenario NetCDF files spanning historical years through 2100 for EcoSIM or related biogeochemical forcing workflows.
日本語の概要は準備中です。原文の説明を表示しています。
Generate or edit images using AI models (FLUX, Gemini). Use for general-purpose image generation including photos, illustrations, artwork, visual assets, concept art, and any image that isn't a technical diagram or schematic. For flowcharts, circuits, pathways, and technical diagrams, use the scientific-schematics skill instead.
日本語の概要は準備中です。原文の説明を表示しています。